You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Designing drugs that suppress chronic brain inflammation

    SBC: INFLAME THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) involves abnormal metabolism of beta-amyloid and destruction of neurons and synapses. Since the ultimate goal of therapeutic strategies for AD is to protect neurons, we screened a variety of generic drugs for neuroprotective effect using cell culture and animals models of AD immune pathology. One widely used generic drug with anti-infl ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  2. PREDICTABLE REAL-TIME MULTIPROCESSING IN AIRBORNE SYSTEMS

    SBC: Unisoft Consulting Inc            Topic: N/A

    N/A

    SBIR Phase I 1996 National Aeronautics and Space Administration
  3. Monoclonal Antibody to Factor B as Therapeutic in Asthma

    SBC: TALIGEN THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Asthma is a chronic, potentially debilitating disease caused by inflammation of the small airways, leading to the clinical symptoms of wheezing and shortness of breath. It is now estimated that asthma affects 20-25 million individuals in the United States and many more worldwide. The prevalence of the disease has nearly doubled in the past two decades and cont ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  4. ADULT HUMAN PROGENITOR CELLS FOR CARDIAC REGENERATION

    SBC: KARDIA THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The ability to create new cardiac tissue using progenitor cells via engraftment would be a significant advance. However, the existing types of progenitor cells presently in Phase I clinical trials face significant limitations, including lack of evidence that the donor cells (1) produce new cardiac myocytes, versus creating benefits via neoangiogenesis or ventr ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  5. Sensitive expression profiling in fixed archived tissue

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Archives of formalin-fixed paraffin embedded (FFPE) human histological tissue samples, probably numbering in the millions of tissue blocks, constitute a tremendous, yet underutilized, historical resource for studying gene expression changes associated with human disease states. Unlike freshly acquired samples, there is usually greater documented medical hist ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  6. Validation of a RSK-inhibitor as a Novel Therapeutic for

    SBC: LUNA INNOVATIONS INCORPORATED            Topic: N/A

    DESCRIPTION (provided by applicant): The inactivation of the host immune response by Yersinia, the causative agent of the plague, is mediated by a family of six proteins called Yersinia outer proteins, or Yops, namely YopE, YopH, YopO, YopM, YopJ, and YopT. While the mechanisms of action of YopE, YopH, YopO, YopJ, and YopT are fairly well understood, the effects of YopM on the host response to Yer ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  7. Nanoparticle-Based Optical Sensor for Glucose Monitoring

    SBC: Biotex, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Diabetes mellitus is a metabolic disease which currently afflicts some 16 million in the US and 100 million people worldwide. In the US, diabetes and its associated complications are the seventh leading cause of death. Effective management of diabetes requires regular measurement of blood sugar, and improvements in glucose sensing technology will enable supe ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  8. Nano-Apatite Coating of the Porous Surface of Implants

    SBC: Nano Interface Technology, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The rate of hip replacement has increased to 21% in the last five years. The proportion of hip or knee replacement procedures that needed revision remained in between 16% and 17%. The cemented total hip replacement is normally preferred but cemented implants have only 10-12 years of life span. The osteolysis caused by the fragments of the cement and corrosion i ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Ceramic Microchannel Plates for Biomedical Imaging

    SBC: SYNKERA TECHNOLOGIES INC            Topic: N/A

    DESCRIPTION (provided by applicant): Biomedical imaging, such as fluorescence microscopy and autoradiography, constantly raises the bar for sensitivity and spatial and temporal resolution of imaging detectors. Many advanced detectors used in biomedical imaging, including intensified CCD cameras, utilize microchannel plates (MCPs), which are solidstate electron multipliers, to intensify weak im ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  10. A Novel Combination Therapy for Smoking Cessation

    SBC: CARY PHARMACEUTICALS INC            Topic: N/A

    Cigarette smoking is the leading preventable cause of death in this country and is an increasing threat to health worldwide. Current pharmacological therapies prescribed for smoking cessation are efficacious. However, the absolute success rates per quit attempt are low (15-35% at one year). The National Institutes of Health recognize the impact that nicotine addiction has on morbidity/mortality, a ...

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government